Pfizer secures up to $1.5B for obesity drug development
Pfizer has reached a co-funding agreement with Blackstone Life Sciences that will provide up to $1.5 billion in development funding through 2028 for its investigational obesity drug berobenatide. Under the agreement, funds managed by Blackstone will cover development costs for berobenatide, a potential first-in-class monthly GLP-1 receptor agonist being studied for chronic weight management and […] The post Pfizer secures up to $1.5B for obesity drug development appeared first on Becker�...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.